Document is current
Any future updates will be listed below
-
Authors
Hamarsheh, Shaima’a https://orcid.org/0000-0003-3991-5542
Osswald, Lena
Saller, Benedikt S.
Unger, Susanne
De Feo, Donatella
Vinnakota, Janaki Manoja
Konantz, Martina
Uhl, Franziska M.
Becker, Heiko
Lübbert, Michael
Shoumariyeh, Khalid
Schürch, Christoph
Andrieux, Geoffroy
Venhoff, Nils
Schmitt-Graeff, Annette
Duquesne, Sandra
Pfeifer, Dietmar
Cooper, Matthew A. https://orcid.org/0000-0003-3147-3460
Lengerke, Claudia https://orcid.org/0000-0001-5442-2805
Boerries, Melanie
Duyster, Justus
Niemeyer, Charlotte M.
Erlacher, Miriam https://orcid.org/0000-0002-7261-1447
Blazar, Bruce R.
Becher, Burkard https://orcid.org/0000-0002-1541-7867
Groß, Olaf
Brummer, Tilman
Zeiser, Robert
- License Information
-
More Information
Article History
Received: 7 September 2019
Accepted: 11 March 2020
First Online: 3 April 2020
Competing interests
: B.R.B. receives remuneration as an advisor to Kamon Pharmaceuticals, Inc., Five Prime Therapeutics Inc., Regeneron Pharmaceuticals, Magenta Therapeutics and BlueRock Therapeutics; research support from Fate Therapeutics, RXi Pharmaceuticals, Alpine Immune Sciences, Inc., Abbvie Inc., BlueRock Therapeutics Leukemia and Lymphoma Society, Childrens’ Cancer Research Fund, KidsFirst Fund and is a co-founder of Tmunity. The other authors have no conflict of interest to disclose.
